Acaricides

Elanco Animal Health Introduces First Oral Flea and Tick Product for Cats, Credelio® CAT (lotilaner)

Retrieved on: 
Tuesday, May 4, 2021

b'Veterinarians in the U.S. now have a new, innovative option for flea and tick control as Elanco Animal Health Incorporated (NYSE: ELAN) introduces Credelio Cat, the first oral flea and tick product for cats.\nCredelio Cat starts killing fleas on cats within 6 hours.

Key Points: 
  • b'Veterinarians in the U.S. now have a new, innovative option for flea and tick control as Elanco Animal Health Incorporated (NYSE: ELAN) introduces Credelio Cat, the first oral flea and tick product for cats.\nCredelio Cat starts killing fleas on cats within 6 hours.
  • The small, chewable product maintains fast-acting, sustained flea efficacy throughout the month in cats 8 weeks and older.
  • \xe2\x80\x9cIt\xe2\x80\x99s great to have a first-of-its-kind flea and tick option for cat owners who prefer oral administration or want to try something besides a topical.
  • The effectiveness of Credelio CAT against black-legged ticks in kittens less than 6 months of age has not been evaluated.

Clinical Trial Conducted by MedinCell Confirms the Safety of Continuous Administration of Ivermectin

Retrieved on: 
Monday, April 19, 2021

Proving the safety of ivermectin in regular daily administration over a long period was an essential step for our ivermectin programs, in particular mdc-TTG in Covid-19," said Jo\xc3\xabl Richard, Chief Development Officer at MedinCell.\nMedinCell is a clinical stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO\xc2\xae technology with active ingredients already known and marketed.

Key Points: 
  • Proving the safety of ivermectin in regular daily administration over a long period was an essential step for our ivermectin programs, in particular mdc-TTG in Covid-19," said Jo\xc3\xabl Richard, Chief Development Officer at MedinCell.\nMedinCell is a clinical stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO\xc2\xae technology with active ingredients already known and marketed.
  • Through the controlled and extended release of the active pharmaceutical ingredient, MedinCell makes medical treatments more efficient, particularly thanks to improved compliance, i.e.
  • compliance with medical prescriptions, and to a significant reduction in the quantity of medication required as part of a one-off or chronic treatment.
  • Based in Montpellier, MedinCell currently employs more than 140 people representing over 25 different nationalities.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210419005658/en/\n'

Front Line COVID-19 Critical Care Alliance Statement on Weak Guidance on Ivermectin from the World Health Organization (WHO)

Retrieved on: 
Thursday, April 1, 2021

The latest guidance from WHO ignores several large clinical trials where ivermectin was proven to prevent mortality by more than 68%.

Key Points: 
  • The latest guidance from WHO ignores several large clinical trials where ivermectin was proven to prevent mortality by more than 68%.
  • The latest guidance from the WHO is out of alignment with many national and local health authorities around the world where ivermectin has been proven to prevent and treat COVID-19.
  • "To ignore the data the way the WHO has, does a disservice to science and to public health.
  • Now, the FLCCC's new I-Mask+ Prophylaxis and Early At-Home Outpatient Treatment Protocol with Ivermectin has been released and is a potential solution to the global pandemic.

FLCCC Alliance Convenes Global Panel That Warns World Governments of the Consequences of Not Deploying Ivermectin for COVID-19

Retrieved on: 
Friday, March 19, 2021

"For a government to continue not to take action on ivermectin is to let people suffer from this terrible disease."

Key Points: 
  • "For a government to continue not to take action on ivermectin is to let people suffer from this terrible disease."
  • The experts also discussed the extensive body of science showing ivermectin as a safe and effective preventative and treatment for COVID-19.
  • Their MATH+ Hospital Treatment Protocol introduced in March 2020, has saved thousands of patients who were critically ill with COVID-19.
  • Now, the FLCCC's new I-Mask+ Prophylaxis and Early At-Home Outpatient Treatment Protocol with Ivermectin has been released and is a potential solution to the global pandemic.

More Medical and Scientific Authorities Around the World Recognize Ivermectin as a Safe and Effective Prevention and Treatment for COVID-19

Retrieved on: 
Monday, March 15, 2021

The discussions will include the latest data on how ivermectin has reduced positive COVID-19 cases in major cities across the world, ivermectin's role in early treatment of COVID-19, and why ivermectin needs to be immediately adopted as a safe and effective prevention and treatment of COVID-19.

Key Points: 
  • The discussions will include the latest data on how ivermectin has reduced positive COVID-19 cases in major cities across the world, ivermectin's role in early treatment of COVID-19, and why ivermectin needs to be immediately adopted as a safe and effective prevention and treatment of COVID-19.
  • The panel discussion will take place at 11:00am 12:00pm ET on Thursday, March 18, 2021 via video conference.
  • Their MATH+ Hospital Treatment Protocol introduced in March 2020, has saved thousands of patients who were critically ill with COVID-19.
  • Now, the FLCCC's new I-Mask+ Prophylaxis and Early At-Home Outpatient Treatment Protocol with Ivermectin has been released and is a potential solution to the global pandemic.

Front Line COVID-19 Critical Care Alliance Statement on Misleading FDA Guidance on Ivermectin

Retrieved on: 
Sunday, March 7, 2021

WASHINGTON, March 7, 2021 /PRNewswire-PRWeb/ -- The Front Line COVID-19 Critical Care Alliance (FLCCC), a group of highly published, world-renowned critical care physicians and scholars, is troubled by the recently updated consumer guidance on Ivermectin from the FDA.

Key Points: 
  • WASHINGTON, March 7, 2021 /PRNewswire-PRWeb/ -- The Front Line COVID-19 Critical Care Alliance (FLCCC), a group of highly published, world-renowned critical care physicians and scholars, is troubled by the recently updated consumer guidance on Ivermectin from the FDA.
  • The guidance from the FDA is misleading and has the potential to raise unwarranted concern over an important drug in the prevention and treatment of COVID-19.
  • However, the FLCCC feels that other statements recently made by the FDA are misleading and serve to alarm the public about using Ivermectin as a treatment prescribed by a physician.
  • The FDA consumer guidance statement admits that they have not reviewed data on the use of Ivermectin to treat or to prevent COVID-19.

An FLCCC Special Virtual Event: "Eliminating the Fear-- How Teachers Can Go Back Into The Classroom Safely"

Retrieved on: 
Thursday, February 18, 2021

Registration is required for the free one-hour event, featuring Dr. Eric Osgood, FLCCC Clinical Advisor.

Key Points: 
  • Registration is required for the free one-hour event, featuring Dr. Eric Osgood, FLCCC Clinical Advisor.
  • Ivermectin is on the WHO's list of essential medicines, and has been given more than 4 billion times around the globe.
  • The teachers say they're most worried about the coronavirus spreading at schools, and how that might endanger their students, themselves and their own families."
  • Their MATH+ Hospital Treatment Protocol introduced in March, 2020, has saved thousands of patients who were critically ill with COVID-19.

Boehringer Ingelheim receives EMA marketing authorization for NexGard® COMBO, the first isoxazoline-based full endectocide for cats

Retrieved on: 
Wednesday, January 13, 2021

Boehringer Ingelheim, a global leader in animal health, is proud to announce that it has received marketing authorization from the EMA (European Medicine Agency) and European Commission for its NexGard COMBO topical solution for cats.

Key Points: 
  • Boehringer Ingelheim, a global leader in animal health, is proud to announce that it has received marketing authorization from the EMA (European Medicine Agency) and European Commission for its NexGard COMBO topical solution for cats.
  • NexGard COMBO offers unparalleled protection for cats: It kills a broader range of parasites than any other isoxazoline-based cat parasiticide currently available on the market.
  • NexGard COMBO is the first isoxazoline-based full endectocide developed specifically for cats, shares Dr. Craig Beck, Global Franchise Head NexGard, Boehringer Ingelheim Animal Health.
  • Were dedicated to being the global leader in feline health care and the launch of NexGard COMBO for cats expands our trusted feline product portfolio.

Covid-19: MedinCell Presents Positive First Results From the Clinical Trial Aiming at Validating the Safety of Continuous Administration of Ivermectin

Retrieved on: 
Thursday, December 17, 2020

Studys first results presented at the international Collaborative Workshop Ivermectin against Covid-19 held on December 15, 16 and 17 at the initiative of MedinCell.

Key Points: 
  • Studys first results presented at the international Collaborative Workshop Ivermectin against Covid-19 held on December 15, 16 and 17 at the initiative of MedinCell.
  • No side effects observed with the first two doses in the study, which includes a total of three doses.
  • A first long-acting injectable formulation is ready to enter regulatory development.
  • Through the controlled and extended release of the active pharmaceutical ingredient, MedinCell makes medical treatments more efficient, particularly thanks to improved compliance, i.e.

Early Home Treatment for COVID-19 Needed NOW, States Physicians for Civil Defense

Retrieved on: 
Wednesday, December 9, 2020

It was serendipitously found to benefit nursing home patients exposed to COVID, who were being treated for scabies.

Key Points: 
  • It was serendipitously found to benefit nursing home patients exposed to COVID, who were being treated for scabies.
  • A meta-analysis of 21 studies has shown ivermectin to be beneficial in early disease, late disease, and both pre-exposure and post-exposure prophylaxis.
  • The federal response to this deadly disease, which she described as "therapeutic nihilism," is "shocking and unprecedented," stated Physicians for Civil Defense president Jane M. Orient, M.D.
  • Physicians for Civil Defense provides information to help save lives in the event of natural or man-made disasters.